The TFE3-ASPL gene fusion has been shown to upregulate pro-inflammatory cytokines and promote an angiogenic and proliferative microenvironment, that probably confers a unique sensitivity of these tumours to anti-angiogenic agents. The gene discussed is ASPSCR1; the disease is neoplasm.